Onco-Innovations Limited
ONNVF
$1.10
-$0.09-7.56%
OTC PK
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 254.93% | -38.26% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 254.93% | -38.26% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 254.93% | -38.26% | |||
| SG&A Expenses | 403.06% | -56.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 291.25% | -39.29% | |||
| Operating Income | -292.15% | 39.32% | |||
| Income Before Tax | -34.84% | 31.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -34.84% | 31.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -34.84% | 31.39% | |||
| EBIT | -292.15% | 39.32% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -30.16% | 55.66% | |||
| Normalized Basic EPS | -30.00% | 18.73% | |||
| EPS Diluted | -30.16% | 55.66% | |||
| Normalized Diluted EPS | -30.00% | 18.73% | |||
| Average Basic Shares Outstanding | 3.48% | 54.85% | |||
| Average Diluted Shares Outstanding | 3.48% | 54.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||